The Sirt1 Activator SRT1720 Mitigates Human Monocyte Activation and Improves Outcome During Gram-Negative Pneumosepsis in Mice
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199309 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Mathieu Blot und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Infection & Molecular Medicine, Amsterdam University Medical Center, Location Academic Medical Center, University of Amsterdam, 1105 AZ Ams…. Hauptthemen laut MEDLINE: Sirtuin 1, Monocytes, Heterocyclic Compounds, 4 or More Rings, Pneumonia, Bacterial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CMIT (french college of university Professors in infectious Diseases), RICAI (french congress of microbiology and infectious diseases), ESCMID (European Society of Clinical Microbiology and Infectious Diseases).
Abstract (Originalsprache)
Community-acquired pneumonia (CAP) is a leading cause of death, with mortality linked to an unbalanced host response. Sirtuin (Sirt)1, a histone deacetylase, regulating metabolism and epigenetics, may be fundamental in activating the innate immune response. Sirt1 mRNA expression was significantly reduced in monocytes from CAP patients (n = 76) upon admission compared to healthy controls (n = 42), with levels returning to normal after 30 days. Pharmacological activation of Sirt1 with SRT1720 decreased LPS- and K. pneumoniae-induced IL-6 release in primary human monocytes and decreased NF-κB activation in THP1 cells. In a mouse K. pneumoniae pneumosepsis model, SRT1720 strongly reduced neutrophil influx and degranulation markers in bronchoalveolar lavage fluid, lowered pulmonary concentrations of IL-6 and TNF-α, and reduced lung pathology scores. Simultaneously, it reduced neutrophil content in liver tissue and plasma transaminase levels, alongside a trend toward reduced liver necrosis. Plasma IL-6 and TNF-α were significantly lower in SRT1720-treated mice at 42 h. Finally, while SRT1720 did not impact bacterial loads in the lungs, it reduced bacterial burden in blood, with a similar trend observed in liver homogenates. In conclusion, the Sirt1 activator SRT1720 exerts anti-inflammatory effects on human monocytes, reduces local and systemic inflammation and organ injury, and diminishes bacterial dissemination in murine pneumosepsis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Infection & Molecular Medicine, Amsterdam University Medical Center, Location Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
- Amsterdam Infection & Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
- Département de Maladies Infectieuse, Hôpital Universitaire Dijon-Bourgogne, 21079 Dijon, France.
- Labex LipSTIC, LNC UMR1231, INSERM, Université Bourgogne-Europe, 21078 Dijon, France.
- Department of Pathology, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
- Division of Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
ORCID-Profile: Mathieu Blot, Valentine Léopold, Alex F de Vos
Förderung
- CMIT (french college of university Professors in infectious Diseases)
- RICAI (french congress of microbiology and infectious diseases)
- ESCMID (European Society of Clinical Microbiology and Infectious Diseases)
Zitieren
APA
Blot, M., Léopold, V., de Beer, R., Florquin, S., Butler, J. M., Van't Veer, C., de Vos, A. F., & van der Poll, T. (2025). The Sirt1 Activator SRT1720 Mitigates Human Monocyte Activation and Improves Outcome During Gram-Negative Pneumosepsis in Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199309
Vancouver
Blot M, Léopold V, de Beer R, Florquin S, Butler JM, Van't Veer C, et al. The Sirt1 Activator SRT1720 Mitigates Human Monocyte Activation and Improves Outcome During Gram-Negative Pneumosepsis in Mice. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199309
BibTeX
@article{Blot2025,
author = {Blot, Mathieu and Léopold, Valentine and de Beer, Regina and Florquin, Sandrine and Butler, Joe M and Van't Veer, Cornelis and de Vos, Alex F and van der Poll, Tom},
title = {The Sirt1 Activator SRT1720 Mitigates Human Monocyte Activation and Improves Outcome During Gram-Negative Pneumosepsis in Mice},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199309}
}
EUVIMED